Federal Stem Cell Funding Blocked
August 24th, 2010
No comments
A US District Court judge has temporarially blocked regulations regarding expansion of of stem cell research. Read more…
Recombinant Human Platelet’s Orphan Drug Designation, BioMimetic Therapeutics (NASDAQ: BMTI)
August 23rd, 2010
No comments
BMTI has received orphan drug designation from the FDA for its protein therapeutic, recombinant human platelet derived growth factor (rhPDGF-BB), Read more…
Categories: Orphan Drug Status, Regenerative Medicine
Phase 3 Bone Marrow Transplant Trial, Mesoblast (ASX:MSB; ADR:MBLTY)
August 23rd, 2010
No comments
Australian, Mesoblast Limited (ASX:MSB; ADR:MBLTY), provided guidance on its Phase 3 bone marrow transplant program following a formal meeting with the US FDA. Read more…
Categories: Stem Cell Technology
$243 M Investment for Stem Cell Disease Teams
August 23rd, 2010
No comments
California’s stem cell research funding agency will fund up to $243 M to help move therapies into clinical trials. Read more…
hNSC Breakthrough in Chronic Spinal Cord Injury, StemCells (NASDAQ: STEM)
August 20th, 2010
No comments
STEM published new preclinical data demonstrating proprietary human neural stem cells to restore lost motor function in mice with chronic spinal cord injury. Read more…
Categories: Stem Cell Technology
New Business Unit, Cytovis™, International Stem Cell (OTCBB: ISCO)
August 20th, 2010
No comments
ISCO.OB’s stem cell therapeutic programs focused on protective, transparent corneas (CytoCor™) in the front of the eye and the light-sensitive retinal tissue (CytoRet™) in the back of the eye will be formalized into a new business unit, Cytovis™. Read more…
Categories: Cytovis, Stem Cell Technology
$9.2 M Generated in Warrant Raise, BioTime (Amex:BTIM)
August 20th, 2010
No comments
BTIM completed its warrant discount offer which generated $9,195,422 of proceeds to BTIM Read more…
Categories: Financing, Stem Cell Technology
New ASTM Analyst Review
August 19th, 2010
No comments
The blended valuation model implies a pricing of $4.40 given the fully diluted shares outstanding. The Sum of the Parts estimation of $5.62 is discounted 10% and is significantly above this stocks current price of $1.49. Read more…
Categories: Independent Equity Research, Stem Cell Technology
iPSCs, Potential Treatment for Parkinson’s Disease
August 19th, 2010
No comments
Researchers at the Buck Institute for Age Research used induced pluripotent stem cells, or iPSCs, from humans (to treat rodents) with Parkinson’s Disease, Read more…
Categories: Stem Cell Technology
Regeneration of Injured Nerves
August 19th, 2010
No comments
Researchers for the first time have induced robust regeneration of nerve tissue connections in injured adult spinal cord sites that control voluntary movement. Read more…
Categories: Nerve Regeneration, Regenerative Medicine
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.